Deerfield Management Company, L.P. (Series C) Vera Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$33.72 - $48.82 $135,453 - $196,109	-4,017 Reduced 39.35%	6,191 $223,000
Q1 2024 May 15, 2024	BUY	$14.91 - $49.14 $152,201 - $501,621	10,208 New	10,208 $440,000
Q1 2023 May 15, 2023	BUY	$5.41 - $18.3 $7.03 Million - $23.8 Million	1,300,000 New	1,300,000 $10.1 Million

Others Institutions Holding VERA

# of Institutions

184

Shares Held

55.2M

Call Options Held

134K

Put Options Held

156K

Avoro Capital Advisors LLC New York, NY

4.31M
Shares

$182 Million
2.87% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.94M
Shares

$167 Million
0.02% of portfolio
Black Rock Inc. New York, NY

3.34M
Shares

$141 Million
0.0% of portfolio
Abingworth LLP London, X0

2.96M
Shares

$125 Million
19.0% of portfolio
Sofinnova Investments, Inc. Menlo Park, CA

2.79M
Shares

$118 Million
11.68% of portfolio

View Full List

About Vera Therapeutics, Inc.

Ticker VERA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,042,300
Market Cap $1.14B
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...

More about VERA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account